Hyperthyroidism occurs when the thyroid gland produces too much thyroid hormone, accelerating metabolism and causing symptoms including rapid heartbeat, weight loss, tremor, anxiety, and heat intolerance. The most common cause is Graves' disease, an autoimmune condition, though thyroid nodules and thyroiditis also cause excess hormone production.
What's actually going on in research
Current treatments include antithyroid drugs such as methimazole, radioactive iodine ablation, and surgery, each with different trade-offs. Trials are testing new approaches targeting the underlying autoimmunity in Graves' disease — particularly drugs that block thyroid-stimulating hormone receptor antibodies — aiming for disease remission rather than just hormone control. Long-term cardiovascular consequences of hyperthyroidism and subclinical disease are also being studied.
TSH receptor antibody blockade
Iscalimab and other drugs targeting the TSH receptor pathway or the B cells that produce stimulating antibodies are in trials aiming to induce lasting remission in Graves' hyperthyroidism without ablation.
Subclinical hyperthyroidism outcomes
Trials are studying whether treating subclinical hyperthyroidism — elevated thyroid hormone with normal or suppressed TSH but minimal symptoms — reduces atrial fibrillation, bone loss, and cardiovascular risk.
Post-ablation quality of life
Studies are examining quality-of-life outcomes, hypothyroidism burden, and patient preference between radioactive iodine, surgery, and long-term antithyroid drug therapy for Graves' disease.
What to know before you search
Eligibility depends on the underlying cause of hyperthyroidism, TSH receptor antibody status, prior treatment, and presence of thyroid eye disease.
What types of trials are currently open
- Immunotherapy trials — Testing drugs targeting TSH receptor antibodies or B cells to induce remission in Graves' disease.
- Antithyroid drug trials — Evaluating optimal dosing, duration, and tapering of methimazole and propylthiouracil.
- Subclinical disease trials — Studying whether treating mild hormone excess prevents cardiovascular and bone complications.
- Thyroid eye disease trials — Evaluating therapies for the orbital inflammation that accompanies some Graves' hyperthyroidism cases.
- Comparative treatment trials — Directly comparing radioactive iodine, surgery, and medical therapy for long-term outcomes and quality of life.
Recently added Hyperthyroidism trials
Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism
Hyperthyroidism is a clinical syndrome caused by excessive production of thyroid hormones, leading to accelerated metabolism and increased excitability of multiple organ systems. Patients commonly present with polyphagia, weight loss, palpitations, and sweating. Primary hyperthyroidism is a common endocrine disorder traditionally treated with anti-thyroid drugs (ATD), radioactive iodine (¹³¹I), or surgery. While ATD can rapidly inhibit thyroid hormone synthesis and control symptoms, long-term use carries risks of liver damage and bone marrow suppression. Radioactive iodine involves risks of recurrence or permanent hypothyroidism, and thyroidectomy-though effective-is associated with significant trauma, potential complications, and cervical scarring. Given the limitations of these monotherapies, a combined approach leveraging thermal ablation as an adjunct to antithyroid drug therapy has emerged as a promising strategy for both rapid symptom control and long-term management. With advances in minimally invasive techniques, thermal ablation combined with pharmacotherapy offers a balanced solution. Thermal ablation-including microwave and radiofrequency ablation-provides high precision, minimal invasiveness, and rapid recovery by directly destroying hyperfunctioning thyroid tissue under ultrasound guidance. When paired with a tailored antithyroid drug regimen, this approach not only secures immediate stabilization of thyroid function but also reduces the required drug dosage and duration, thereby mitigating drug-related adverse effects. This combined strategy maintains the cosmetic and cost-effective advantages of ablation while addressing the need for sustained endocrine control. Studies have demonstrated that thermal ablation combined with antithyroid drugs effectively normalizes T3 and T4 levels, alleviates hypermetabolic symptoms such as palpitations and sweating, and significantly improves quality of life with a low complication rate. This integrated model is suitable for initial treatment, recurrent or refractory cases, and is particularly advantageous for patients with reduced cardiopulmonary reserve or advanced age. However, current evidence is largely derived from single-center studies, and high-quality multicenter data are needed to validate this combined strategy. This study aims to prospectively collect baseline data from patients undergoing thermal ablation in conjunction with antithyroid drug therapy across multiple centers. The objectives are to evaluate the efficacy and safety of this combined modality, explore the factors influencing the prognosis of ablation in a medicated context, optimize postoperative medication adjustment protocols, and provide high-quality evidence to guide the standardization and clinical dissemination of this synergistic approach.
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain. Currently, intravenous glucocorticoids (steroids) are the standard first-line treatment. However, approximately 20-30% of patients do not respond to steroids, or cannot tolerate their side effects. This study aims to evaluate the safety and efficacy of Tofacitinib, an oral medication known as a Janus kinase (JAK) inhibitor, as a rescue therapy for these difficult-to-treat cases. Tofacitinib works by blocking specific signaling pathways (JAK-STAT) that drive inflammation and fibrosis in the eye socket. In this study, patients with moderate-to-severe active TED who are resistant to or intolerant of steroids will receive Tofacitinib tablets (5 mg twice daily) for 24 weeks. The researchers will assess whether the treatment can effectively reduce eye bulging and improve clinical activity scores.
Find Hyperthyroidism trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.